

ASX Release

SUDA PHARMACEUTICALS: ANAGRELIDE UPDATE

PERTH, AUSTRALIA – 12 JULY 2018: SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oro-mucosal drug delivery announced today that it has made some significant breakthroughs in its pre-clinical formulation of anagrelide using its OroMist® technology. Anagrelide is a novel anti-cancer agent that is receiving widespread global interest.

SUDA owns the world-wide rights to anagrelide as a preventative/treatment of cancer in patients with elevated platelet counts. SUDA plans to formulate an oro-mucosal spray of anagrelide utilising the Company's OroMist® technology which could potentially avoid the side-effects associated with the molecule when administered as an oral solid dose.

Anagrelide is an inherently insoluble compound which creates challenges in formulation of an oral solution. SUDA scientists have managed to increase the solubility of anagrelide by a factor of approximately 60 fold allowing SUDA to achieve potentially therapeutic doses with its OroMist® spray technology. This breakthrough has now provided SUDA scientists with a basis for further formulation work.

We have previously noted that anagrelide is currently used as an anti-thrombotic agent to reduce elevated levels of platelets. It is now well recognised that platelets play an important role in the growth and metastatic spread of tumours. Since this time, there have been a number of publications not only consolidating the role that platelets play in cancer malignancies but, more importantly, providing data that confirms that lowering platelet numbers results in an improved overall survival rate in patients with a number of solid tumours.

Further data has also shown that platelets play a role in a patient developing drug resistance. This data suggests that targeting platelets is a potential strategy to overcome the problem of chemoresistance.

The global market for cancer drugs has grown to more than \$100 billion in annual sales. Newer cancer treatments include immunotherapies that stimulate the patient's own immune system.

It is our belief that anagrelide would be complementary to such treatments by reducing the platelet numbers thereby reducing the proliferative and protective effect that platelets exhibit on metastatic cells and further rendering circulating cancer cells more susceptible to attack by the body's own killer cells. Thus, it potentially offers a novel and valuable first-in-class treatment option for cancer.



Further information:

STEPHEN CARTER

CHIEF EXECUTIVE OFFICER / MANAGING DIRECTOR

SUDA Pharmaceuticals Ltd

Tel: +61 8 6142 5555

sjcarter@sudapharma.com

NOTES TO EDITORS:

About SUDA Pharmaceuticals Ltd

SUDA Pharmaceuticals Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e.: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist™, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist is marketed in the USA and SUDA has rights to the product outside of the US and Canada. SUDA has submitted a Marketing Authorisation Application to the Australian Therapeutic Goods Administration for ArTiMist®, its novel sublingual malaria treatment for children. In a Phase III trial, ArTiMist was shown to be superior to intravenous quinine. Other products in development include oral sprays for the treatment of migraine headache, chemotherapy-induced nausea and vomiting, erectile dysfunction, PAH, epileptic seizures and pre-procedural anxiety. For more information, visit www.sudapharma.com